News


November 8th, 2017

Qu Biologics recruits Ms. Jennifer Archibald, Chief Financial Officer, and Mr. Alun Rees, VP, Manufacturing, to Leadership Team

Vancouver, British Columbia – November 8th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has brought on board two highly experienced biotech executives, to round out the leadership team of the company. Ms. Jennifer Archibald has joined […]

READ MORE >
October 19th, 2017

Research Technician

TERMS OF EMPLOYMENT This posting is for a full-time (1.0 FTE) position on a 12-month contract to cover an employee on maternity leave. COMPANY PROFILE Qu Biologics is a private, clinical-stage biopharmaceutical company located in Vancouver, BC, that develops Site Specific Immunomodulators (SSIs) which are designed to restore the body’s normal immune function to reverse […]

READ MORE >
October 3rd, 2017

Response to Novel Immune Therapy for Ulcerative Colitis Associated with Genetic and Immune Biomarkers

Vancouver, British Columbia – October 3rd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has identified specific ulcerative colitis (UC) genetic markers that may predict response to QBECO SSI therapy and important immunological biomarkers that may be […]

READ MORE >
August 15th, 2017

Process Development Associate

TERMS OF EMPLOYMENT This is a full-time position (1.0 FTE) COMPANY PROFILE Qu Biologics is a private, clinical-stage biopharmaceutical company located in Vancouver, BC, that develops Site Specific Immunomodulators (SSIs) which are designed to restore the body’s normal immune function to reverse the chronic inflammation underlying many conditions including cancer and inflammatory bowel diseases (IBD). […]

READ MORE >
August 14th, 2017

Positive feedback from FDA reviewers in response to Pre-IND meeting package

Vancouver, British Columbia – August 14th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports positive and informative feedback from the US Food and Drug Administration (FDA) in response to Qu’s first Pre-IND meeting package submission. The […]

READ MORE >
August 2nd, 2017

Treatment with Qu Biologics’ Novel Immune Therapy for Ulcerative Colitis Results in High Clinical and Endoscopic Response Rates and Histological Improvement

Vancouver, British Columbia – August 2nd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports high clinical and endoscopic response rates in its recently completed Phase 2, open-label, dose ranging trial in study participants with moderate to […]

READ MORE >
August 2nd, 2017

Qu Biologics invited to present at US National Cancer Institute (NCI) Conference

Vancouver, British Columbia – July 12th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, is pleased to announce that CEO Dr. Hal Gunn, was invited to present at the US National Cancer Institute’s Microbial-Based Cancer Therapy Conference […]

READ MORE >
August 1st, 2017

Chief Financial Officer

TERMS OF EMPLOYMENT This is a full-time, permanent position (1.0 FTE; min. 40 hours/week) COMPANY PROFILE Qu Biologics (‘Qu’) is a private, clinical-stage biopharmaceutical company located in Vancouver, BC, that develops Site Specific Immunomodulators (SSIs) which are designed to restore the body’s normal immune function to reverse the chronic inflammation underlying many conditions including cancer […]

READ MORE >
July 7th, 2017

More Qu Biologics international research presentations

Dr Hal Gunn, CEO of Qu Biologics, has been invited to present at the US National Cancer Institute (NCI) Conference on Microbial-Based Cancer Therapy. His topic for presentation is “Site-Specific Immunomodulators: Harnessing the Intrinsic Immune Capacity to Prevent and Fight Malignancy”.  Initiated by the NCI Office of Cancer Complementary and Alternative Medicine, the aim of this […]

READ MORE >
May 24th, 2017

Qu Biologics Publishes Proof-of-Principle Data for Promising New Treatment for Chronic Obstructive Pulmonary Disease (COPD)

Vancouver, British Columbia – May 23, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) designed to “reboot” the body’s innate immune system, announces the peer-reviewed publication of proof of principle data in chronic obstructive pulmonary disease (COPD) in the journal, Respiratory Research.  The study demonstrates success with Qu Biologics’ QBKPN SSI in reducing […]

READ MORE >

Past events:


Past events: